IceCure Medical Ltd. (NASDAQ:ICCM) shares are soaring Wednesday after the company reported a 70% jump in its U.S. commercial install base for ProSense, its breast cancer cryoablation system. Here’s what you should know.
- IceCure Medical stock is showing exceptional strength. What’s fueling ICCM momentum?
Install Base Expands 70% After FDA Authorization
IceCure announced that its active United States install base for ProSense grew 70% following FDA marketing authorization in October 2025. The company said the increase reflects faster commercial adoption, rising physician demand and broader expansion of its United States presence.
IceCure has continued placing new ProSense systems in clinics and hospitals across the country. Procedures are now being performed in major metropolitan areas such as Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix and Memphis.
Growing Physician And Clinical Interest
The company reported strong engagement at two major breast health conferences earlier this year. These included the Society of Breast Imaging Annual Symposium and the American Society of Breast Surgeons Annual Meeting. IceCure said both events generated far more sales leads for ProSense than the same conferences in 2025, before FDA authorization.
Clinical guidance has also shifted in the company's favor. The American Society of Breast Surgeons recently updated its Resource Guide to include cryoablation as a local treatment option for low‑risk breast cancer. IceCure said the update shows that more breast surgeons are recognizing the potential role of cryoablation for carefully selected patients.
CEO Eyal Shamir said the company believes it is still in the early stages of a large commercial opportunity in the United States. He noted rising physician interest, broader clinical acceptance and increasing patient awareness. Shamir added that IceCure is focused on expanding its install base, supporting physicians through training and education and improving patient access to ProSense.
Critical Technical Levels For ICCM Stock
IceCure remains in a broader downward trend even after the latest surge. The stock trades about 12.9% below the 50‑day simple moving average at $7.29, roughly 48.2% below the 100‑day simple moving average at $12.25 and close to 65% below the 200‑day simple moving average at $18.14. These levels matter because traders who bought at higher prices often sell into strength when the stock approaches long‑term averages, creating what is known as overhead supply.
In the short term, IceCure now sits about 30% above the 20‑day simple moving average at $4.89. That gap shows how aggressive the rebound has been compared to the past month of trading. The larger trend damage is still visible, including the bearish crossover pattern that developed after the death cross in July 2025 when the 50‑day average moved below the 200‑day average.
RSI offers the clearest read on momentum. The indicator is at 21.02, which places the stock in oversold territory. This usually signals that selling pressure has pushed the stock too far to the downside and that sharp countertrend rallies can develop. A rebound can be meaningful without necessarily signaling that the long‑term trend has reversed.
- Key Resistance: $7.50 — This level sits near a round‑number zone close to the 50‑day region where recent rebounds have struggled to continue higher.
ICCM Shares Are Skyrocketing
ICCM Price Action: IceCure shares were up 280.75% at $8.11 at the time of publication on Wednesday, according to Benzinga Pro.
Image: Zakharchuk/Shutterstock.com
Login to comment